BPTHのニュース
Bio-Path Holdings Inc. (BPTH) Q4 2022 Earnings Call Transcript 2023/03/31 14:25:05 Seeking Alpha
Bio-Path Holdings Inc. (NASDAQ:NASDAQ:BPTH) Q4 2022 Earnings Conference Call March 31, 2023 8:30 AM ETCompany ParticipantsWill O''Connor - Stern IRPeter Nielsen - CEO and CFOAnthony Price -…
Bio-Path GAAP EPS of -$1.91 misses by $1.46 2023/03/31 11:02:55 Seeking Alpha
Bio-Path press release (BPTH): Q4 GAAP EPS of -$1.91 misses by $1.46.As of December 31, 2022, the Company had cash of $10.4 million, compared to $23.8 million at December 31, 2021
A Preview Of Bio-Path Holdings''s Earnings 2023/03/30 15:01:06 Benzinga
Bio-Path Holdings (NASDAQ: BPTH ) is set to give its latest quarterly earnings report on Friday, 2023-03-31. Here''s what investors need to know before the announcement. Analysts estimate that Bio-Path Holdings will report an earnings per share (EPS) of $-0.46. Bio-Path Holdings bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023 2023/03/24 20:01:00 GlobeNewswire
HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 31, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022 and to provide a business overview.
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors 2022/12/07 12:00:00 GlobeNewswire
Phase 1/1b Clinical Trial Evaluating Ability of BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer Phase 1/1b Clinical Trial Evaluating Ability of BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer
Bio-Path Holdings Inc.''s (BPTH) CEO Peter Nielsen on Q2 2022 Results - Earnings Call Transcript 2022/08/16 15:34:21 Seeking Alpha
Bio-Path Holdings, Inc. (NASDAQ:NASDAQ:BPTH) Q2 2022 Earnings Conference Call August 16, 2022, 08:30 AM ET Company Participants Will O''Connor - Stern Investor Relations Peter Nielsen - CEO…
Bio-Path Holdings: Q2 Earnings Insights 2022/08/16 11:32:38 Benzinga
Bio-Path Holdings (NASDAQ: BPTH ) reported its Q2 earnings results on Tuesday, August 16, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Bio-Path Holdings beat estimated earnings by 14.29%, reporting … Full story available on Benzinga.com
Bio-Path GAAP EPS of -$0.42 beats by $0.07 (NASDAQ:BPTH) 2022/08/16 11:04:44 Seeking Alpha
Bio-Path press release (BPTH): Q2 GAAP EPS of -$0.42 beats by $0.07.As of June 30, 2022, the Company had cash of $17.0 million, compared to $23.8 million at December 31, 2021.
Bio-Path Holdings Reports Second Quarter 2022 Financial Results 2022/08/16 11:00:00 GlobeNewswire
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
Bio-Path: Q2 Earnings Snapshot 2022/08/16 10:59:37 mySA
BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Monday reported a loss of $3 million in its second quarter. On a per-share basis, the Bellaire, Texas-based company said it had a loss of 42 cents. The company''s shares closed at $4.13. A year ago, they were trading at $6.51. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPTH at https://www.zacks.com/ap/BPTH
Bio-Path Holdings: Q1 Earnings Insights 2022/05/17 11:46:58 Benzinga
Bio-Path Holdings (NASDAQ: BPTH ) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Bio-Path Holdings missed estimated earnings by 4.44%, reporting … Full story available on Benzinga.com
Bio-Path: Q1 Earnings Snapshot 2022/05/17 11:21:21 mySA
BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Monday reported a loss of $3.4 million in its first quarter. On a per-share basis, the Bellaire, Texas-based company said it had a loss of 47 cents. The company''s shares closed at $3.19. A year ago, they were trading at $5.33. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPTH at https://www.zacks.com/ap/BPTH
Bio-Path GAAP EPS of -$0.47 misses by $0.01 2022/05/17 11:04:12 Seeking Alpha
Bio-Path press release (BPTH): Q1 GAAP EPS of -$0.47 misses by $0.01.As of March 31, 2022, the Company had cash of $21.2 million, compared to $23.8 million as of December 31, 2021.
Bio-Path Holdings Reports First Quarter 2022 Financial Results 2022/05/17 11:00:00 GlobeNewswire
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022 2022/05/10 11:00:00 GlobeNewswire
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, May 17, 2022 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2022 and to provide a business overview.